Navigation Links
A transplant in time

In hemophilia, a mutated gene prevents the production of a critical blood-clotting protein. Treatments for hemophilia and other such genetic diseases, when they exist, may consist of risky blood transfusions or expensive enzyme replacement therapy. But what if the body could be induced to begin producing these proteins, say by transplanting healthy tissue with the abilities that are lacking?

Prof. Yair Reisner and Ph.D. student Anna Aronovich of the Weizmann Institute's Immunology Department, together with colleagues, showed, in research recently published in the Proceedings of the National Academy of Sciences (PNAS), how such a transplant might, in the future, be made feasible.

Previous attempts to treat genetic disease by transplanting (mother to daughter) a spleen, an organ that can manufacture a number of the missing proteins in some such diseases, had made little headway due to the fact that the spleen is home to the immune system's T cells ?cells responsible for the severe immune responses against the recipient known as graft-versus-host disease (GVHD).

Reisner and his team revived the idea, with a twist. Over the past several years, he and members of his lab have been experimenting with tissue transplanted from pig embryos ?a possible substitute for human donor organs. From this, they have learned that for each type of tissue, there is a window of opportunity during which cells taken from the developing embryo can be most successfully transplanted. Tissues taken too early, when they are still fairly undifferentiated, may form tumors, while those taken too late can be identified as foreign, causing the host to reject them.

By taking spleen tissue from embryonic pigs over the course of gestation, they found that the harmful T cells are not present in the tissue prior to day 42 of gestation. The scientists also found that tissue of this age exhibits optimal growth potential as well as secreting factor VIII, the blood-clo tting protein missing in hemophilic patients. Thus, the scientists fixed the ideal time for spleen transplantation at 42 days. Hemophiliac mice with spleen tissue transplanted from pig embryos at this time experienced completely normal blood clotting within a month or two of implantation.

Although a number of problems would need to be surmounted before researchers could begin to think of applying the technique to humans, the Institute team's experiment is "proof of principle" ?evidence that transplanted embryonic tissue, whether human or pig, could one day help the body to overcome genetic diseases.
'"/>

Source:American Committee for the Weizmann Institute of Science


Related biology news :

1. Discoveries by UAB and Florida scientists may help transplanted organs survive longer
2. New type of rejection blocker protects kidneys after transplant
3. Monkeying around to improve organ transplantation
4. Researchers identify genes associated with lung transplant rejection
5. Israeli scientists successfully transplant frozen-thawed ovaries in sheep
6. New cell transplantation technique restores insulin production in diabetics
7. New antifreeze protein found in fleas may allow longer storage of transplant organs
8. Implantable pumps extend lives of patients too sick for transplant
9. Infant transplant patients resist infections that kill adult AIDS patients
10. Diabetes researchers pioneer islet cell xenotransplantation in primate studies
11. Carnegie Mellon develops non-invasive technique to detect transplant rejection at cellular level

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/17/2017)... , April 17, 2017 NXT-ID, Inc. (NASDAQ: ... announces the filing of its 2016 Annual Report on Form 10-K ... Commission. ... 10-K is available in the Investor Relations section of the Company,s ... the SEC,s website at http://www.sec.gov . 2016 Year ...
(Date:4/11/2017)... N.Y. , April 11, 2017 ... fingerprints, but researchers at the New York University ... College of Engineering have found that partial similarities ... security systems used in mobile phones and other ... thought. The vulnerability lies in the ...
(Date:4/5/2017)... LONDON , April 4, 2017 KEY ... is anticipated to expand at a CAGR of 25.76% ... neurodegenerative diseases is the primary factor for the growth ... full report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The ... of product, technology, application, and geography. The stem cell ...
Breaking Biology News(10 mins):
(Date:4/20/2017)... ... , ... Parallel6™ , the leader in mClinical™ technologies for improving patient ... one of the 2017 Top 10 eClinical Trial Management Solution Providers by Pharma ... “We take pride in honoring Parallel6 as one of the top 10 companies that ...
(Date:4/20/2017)... Israel , April 20, 2017  BrainStorm Cell ... cell technologies for neurodegenerative diseases, announced today that Chaim ... for Regenerative Medicine,s (ARM) 5 th Annual Cell & ... 09:40 EDT in Boston . ... Medical Officer & Chief Operating Officer, will participate in a ...
(Date:4/19/2017)... ... April 18, 2017 , ... A number of new instruments have recently emerged ... of the Protein and Cell Analysis Education Webinar Series , will focus on ... in current and future applications. , Many flow cytometers have unique capabilities and ...
(Date:4/19/2017)... ... April 19, 2017 , ... Nobilis Therapeutics Announces Completion of ... Leverage Clinical Data in its Upcoming Post Traumatic Stress Disorder Trial , Nobilis ... clinical trial assessing efficacy of its NBTX-001, a xenon-based therapeutic in the treatment of ...
Breaking Biology Technology: